Tags

Type your tag names separated by a space and hit enter

RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine.
Expert Rev Vaccines 2008; 7(10):1475-80ER

Abstract

Rotavirus (RV) is a leading cause of diarrhea worldwide, and will infect every child by their 5th birthday. The 3-dose oral pentavalent RV vaccine (RotaTeq), consisting of serotypes G1, G2, G3, G4 and P1A[8], was licensed in the USA in 2006. The first dose should be administered between the ages of 6 and 12 weeks and the third dose should be given before the age of 32 weeks (USA) or 26 weeks (Europe). In a large clinical trial, the vaccine prevented 74% of cases of RV gastroenteritis, and 98% of cases of severe RV gastroenteritis (based on a symptomatology scoring scale) in the first rotavirus season. Vaccine efficacy in the second season was 62.6% against any RV gastroenteritis and 88% against severe disease. Vaccine efficacy in reducing hospitalizations and emergency department visits was 94.5% up to 2 years after vaccination. Results from a large clinical trial, as well as ongoing postmarketing surveillance, indicate that the vaccine is safe and well tolerated, without evidence of increased risk of intussusception. Further research is needed to establish vaccine efficacy in developing countries, particularly in Africa and Asia. Dissemination efforts should focus on ensuring the vaccine reaches the poorest children in whom disease morbidity and mortality is the highest.

Authors+Show Affiliations

Johns Hopkins Bloomberg School of Public Health, Department of International Health, 615 North Wolfe Street, Suite E8005, Baltimore, MD 21205, USA. archandr@jhsph.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19053204

Citation

Chandran, Aruna, and Mathuram Santosham. "RotaTeq: a Three-dose Oral Pentavalent Reassortant Rotavirus Vaccine." Expert Review of Vaccines, vol. 7, no. 10, 2008, pp. 1475-80.
Chandran A, Santosham M. RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine. Expert Rev Vaccines. 2008;7(10):1475-80.
Chandran, A., & Santosham, M. (2008). RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine. Expert Review of Vaccines, 7(10), pp. 1475-80. doi:10.1586/14760584.7.10.1475.
Chandran A, Santosham M. RotaTeq: a Three-dose Oral Pentavalent Reassortant Rotavirus Vaccine. Expert Rev Vaccines. 2008;7(10):1475-80. PubMed PMID: 19053204.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine. AU - Chandran,Aruna, AU - Santosham,Mathuram, PY - 2008/12/5/pubmed PY - 2009/1/3/medline PY - 2008/12/5/entrez SP - 1475 EP - 80 JF - Expert review of vaccines JO - Expert Rev Vaccines VL - 7 IS - 10 N2 - Rotavirus (RV) is a leading cause of diarrhea worldwide, and will infect every child by their 5th birthday. The 3-dose oral pentavalent RV vaccine (RotaTeq), consisting of serotypes G1, G2, G3, G4 and P1A[8], was licensed in the USA in 2006. The first dose should be administered between the ages of 6 and 12 weeks and the third dose should be given before the age of 32 weeks (USA) or 26 weeks (Europe). In a large clinical trial, the vaccine prevented 74% of cases of RV gastroenteritis, and 98% of cases of severe RV gastroenteritis (based on a symptomatology scoring scale) in the first rotavirus season. Vaccine efficacy in the second season was 62.6% against any RV gastroenteritis and 88% against severe disease. Vaccine efficacy in reducing hospitalizations and emergency department visits was 94.5% up to 2 years after vaccination. Results from a large clinical trial, as well as ongoing postmarketing surveillance, indicate that the vaccine is safe and well tolerated, without evidence of increased risk of intussusception. Further research is needed to establish vaccine efficacy in developing countries, particularly in Africa and Asia. Dissemination efforts should focus on ensuring the vaccine reaches the poorest children in whom disease morbidity and mortality is the highest. SN - 1744-8395 UR - https://www.unboundmedicine.com/medline/citation/19053204/RotaTeq:_a_three_dose_oral_pentavalent_reassortant_rotavirus_vaccine_ L2 - http://www.tandfonline.com/doi/full/10.1586/14760584.7.10.1475 DB - PRIME DP - Unbound Medicine ER -